GlassScriptPhysician profile
Agnes Virga
NPI 1184614414
$15,553.35
in general payments reported to CMS, 2019-2025
40 companies · $2,927 in 2025
The $2,927 reported for 2025 was more than what 93% of Neuromusculoskeletal Medicine, Sports Medicine providers received nationally (typical 2025 total: $125).
See the full distribution for Neuromusculoskeletal Medicine, Sports Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,300 · 2020: $1,609 · 2021: $2,554 · 2022: $2,841 · 2023: $2,106 · 2024: $2,217 · 2025: $2,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,932 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,931.71 |
| Education | $317.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,249.54 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,205.95 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Kyowa Kirin, INC. | $953.10 | 2019-2024 | Nourianz |
| Pfizer INC. | $944.12 | 2023-2025 | |
| Biogen, INC. | $822.44 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $810.39 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Amgen INC. | $810.26 | 2019-2023 | Aimovig |
| Novartis Pharmaceuticals Corporation | $663.25 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $616.35 | 2019-2022 | |
| Celgene Corporation | $573.51 | 2021-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $525.85 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $497.46 | 2022-2025 | Rytary, Crexont, Ongentys |
| Sunovion Pharmaceuticals INC. | $412.46 | 2019-2022 | |
| Allergan, INC. | $403.82 | 2019-2022 | |
| Acorda Therapeutics, INC | $401.15 | 2019-2023 | Inbrija |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Virga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.